Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Drug developer Redx Pharma receives huge vote of confidence in the form of US$1mln grant to develop its next-generation antibiotic

The money from CARB-X will enable Redx to move its Gram-negative antibacterial programme into the next stage of development
Drug developer Redx Pharma receives huge vote of confidence in the form of US$1mln grant to develop its next-generation antibiotic
Pictured Gram-negative bacteria

Drug developer Redx Pharma (LON:REDX) has been awarded a US$1mln grant by a US-UK partnership set up to accelerate the development of new antibiotics that combat drug resistant Gram-negative bacteria.

The money from CARB-X will enable Redx to move its Gram-negative antibacterial programme into the next stage of development with a prospective partner.

WATCH: Grant "testament to great science", saw RedX CSO ...

Chief executive Dr Neil Murray said: “We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics.

“Receiving this grant today is testament to the great science that exists at Redx.

“This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programmes.”

Redx was one of just 11 companies to receive financial backing from CARB-X, one of the world’s largest public-private partnerships.

The money will be staggered over 18 months with an option for future tiered milestone payments “to drive scientific progress against globally challenging drug resistant Gram-negative bacteria”, the company said.

CARB-X was launched by the US Department of Health and Human Services and is funded by the Biomedical Advanced Research and Development Authority and the Wellcome Trust, a UK charity.

Ian_55ae0ddd437b7.jpg
Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use